Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Xin Wang1,*
Jin Deng2,*
Chongxiang Xiong1
Haishan Chen1
Qin Zhou1
Yue Xia1
Xiaofei Shao1
Hequn Zou1

1Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2Department of Nephrology, The First Affiliated Hospital of University of South China, Hengyang, People’s Republic of China

*These authors contributed equally to this work

Purpose: Hyperuricemia is an independent risk factor for renal damage and can promote the progression of chronic kidney disease (CKD). In the present study, we employ a rat model to investigate the effects of rosiglitazone (RGTZ), a peroxisome proliferator-activated receptor-gamma agonist, on the development of hyperuricemic nephropathy (HN), and we elucidate the mechanisms involved.

Methods: An HN rat model was established by oral administration of a mixture of adenine and potassium oxonate daily for 3 weeks. Twenty-four rats were divided into 4 groups: sham treatment, sham treatment plus RGTZ, HN, and HN treated with RGTZ.

Results: Administration of RGTZ effectively preserved renal function, decreased urine microalbumin, and inhibited interstitial fibrosis and macrophage infiltration in a rat HN model. RGTZ treatment also inhibited TGF-β and NF-κB pathway activation, decreased expression of fibronectin, collagen I, α-SMA, vimentin, MCP-1, RANTES, TNF-α, and IL-1β, and increased E-cadherin expression in the kidneys of HN rats. Furthermore, RGTZ treatment preserved expression of OAT1 and OAT3 in the kidney of HN rats.

Conclusion: RGTZ attenuates the progression of HN through inhibiting TGF-β signaling, suppressing epithelial-to-mesenchymal transition, reducing inflammation, and lowering serum uric acid levels by preserving expression of urate transporters.

Keywords: hyperuricemic nephropathy, peroxisome proliferator-activated receptor-gamma, rosiglitazone, renal fibrosis, epithelial-to-mesenchymal transition, inflammation

Introduction
Hyperuricemia is an independent risk factor for renal damage and can promote the progression of chronic kidney disease (CKD).1,2 Hyperuricemia is caused by increased uric acid production and decreased renal excretion. Uric acid is formed in the liver from dietary purines and endogenously synthesized purines. Uric acid is translocated across the basolateral membrane from the bloodstream into proximal tubular cells through organic anion transporters (OAT), including OAT1 (SLC22A6) and OAT3 (SLC22A8), and is then secreted into the tubular lumen.3 Decreased expression of OAT1 and OAT3 can lead to an accumulation of uric acid, leading to hyperuricemic nephropathy (HN).

Mechanisms of renal injury induced by hyperuricemia remain poorly understood. HN is characterized by uric acid kidney stones, glomerular hypertension, arteriolar sclerosis, and tubulointerstitial fibrosis, and can eventually lead to chronic renal failure. Tubulointerstitial fibrosis plays an important role in the renal injury associated with
HN, and excessive deposition of extracellular matrix (ECM) in kidney tissue is a major feature of tubulointerstitial fibrosis.\(^4\) Myofibroblasts are the primary cell type that secretes collagen, and excessive collagen secretion leads to ECM overaccumulation and renal interstitial fibrosis. In renal tissue, tubular epithelial-to-mesenchymal transition (EMT) is a prominent source of myofibroblasts, and plays an important role in renal fibrosis.\(^5,6\) EMT can be induced by many factors, including transforming growth factor β1 (TGF-β1) and uric acid.\(^7,8\) Furthermore, uric acid can also induce inflammation by activating the NF-κB pathway and inducing infiltration of monocytes/macrophages and production of multiple cytokines, such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and regulated on activation, normal T cell expressed and secreted (RANTES).\(^9,10\)

Peroxisome proliferator-activated receptor γ (PPAR-γ) is a ligand-dependent transcription factor belonging to the superfamily of nuclear hormone receptors, and is widely expressed in renal tissues.\(^11,12\) In addition to its glucose-lowering activity in diabetes, PPAR-γ activation also exerts anti-inflammatory and antifibrotic effects in a variety of other diseases.\(^13–15\) However, it remains unclear whether activation of the PPAR-γ pathway is capable of halting or slowing the progression of HN. In this study, we investigated the effects of PPAR-γ activation by RGTZ, a highly selective PPAR-γ agonist, on the development of HN.

**Materials and Methods**

**Antibodies and Reagents**

Antibodies to PPAR-γ were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies to fibronectin, p-NF-kB (p65), NF-kB (p65), and CD68 were purchased from Abcam (Cambridge, MA, USA). Antibodies to collagen I and α-smooth muscle actin (α-SMA) were purchased from Affinity Biosciences (Cincinnati, OH, USA). Antibodies to TGF-β1 were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies to Smad3 and p-Smad3 were purchased from Hangzhou HuaAn Biotechnology Co., Ltd. (Hangzhou, China). Antibodies to E-cadherin and vimentin were purchased from Proteintech (Chicago, IL, USA). Antibodies to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from CWBIO (Beijing, China). RGTZ was purchased from APEXBIO Technology LLC (Houston, TX, USA). Serum XOD kit was purchased from Jiancheng Bioengineering Institute (Nanjing, China). MCP-1, RANTES, TNF-α, and IL-1β ELISA kits were purchased from CUSABIO Technology LLC (Wuhan, China).

**Animals and Experimental Design**

The animal experiments were approved by the Southern Medical University Experimental Animal Ethics Committee. All animal research was conducted in accordance with the Guiding Opinions on the Treatment of Laboratory Animals issued and the Laboratory Animal-Guideline for Ethical Review of Animal Welfare issued by the National Standard GB/T35892-2018 of the People’s Republic of China. Male Sprague–Dawley (SD) rats of specific pathogen free grade, weighing 200–220 g, were purchased from the Experimental Animal Center of Southern Medical University. The rats were housed under standard conditions with controlled 12 h light/dark cycles, temperature, and humidity, and had unrestrained activity and free access to water and food. The rats were allowed 7 days to acclimate to the environment before experiments. The HN rat model was established by oral administration of a mixture of adenine (0.1 g/kg) and potassium oxonate (1.5 g/kg) daily for 3 weeks, as we described previously.\(^10\) Twenty-four male rats were randomized into four treatment groups: sham treatment, sham treatment plus RGTZ (5 mg/kg/d, orally), HN, and HN treated with RGTZ (5 mg/kg/d, orally). For oral administration, RGTZ was dissolved in Carboxymethylcellulose sodium.

**Functional Parameters**

After three weeks, blood samples were taken to measure serum creatinine, blood urea nitrogen, serum uric acid, and other biochemical indices. In addition, 24 hours urine samples were collected, and levels of urine microalbumin and urine uric acid were measured.

**Histology and Immunohistochemistry**

Formalin-fixed kidneys were embedded in paraffin blocks and sections 3 μm in thickness were prepared. Sections were stained with hematoxylin–eosin (HE), Masson’s trichrome, and periodic acid–Schiff (PAS) staining. Renal tissue sections were transferred into a 10 mmol/L citrate buffer solution adjusted to a pH of 6.0. The sections were then treated in a microwave for 20 min for antigen retrieval. Afterwards, endogenous peroxidase activity was inactivated by treatment with 3% hydrogen peroxide. Thereafter, primary antibodies were added dropwise to the renal tissue sections and sections were incubated at
4°C overnight. Sections were then washed with PBS, and incubated in secondary antibody for 30 min at room temperature. The sections were again washed with PBS. Subsequently, the sections were visualized with 3,3′-diaminobenzidine (DAB, Golden Bridge Biotechnology Co., Beijing, China) and counterstained with hematoxylin. Masson’s Trichrome-stained sections from each kidney were graded for the presence of interstitial fibrosis according to the following scale: 0, no evidence of interstitial fibrosis; 1, <25% involvement; 2, 25 to 50% involvement and 3, >50% involvement. The score of each kidney sample was carried out as the average of at least 10 random high-power (×400) fields.16

Western Blotting Analysis
Total protein was extracted from renal tissue samples using RIPA lysis Buffer. The protein concentrations of the samples were measured using a Bicinchoninic Acid (BCA) Protein Assay Kit (Beyotime, Shanghai, China). Equal amounts of total protein were electrophoresed and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% BSA and incubated overnight with primary antibodies at 4°C. Membranes were subsequently incubated with corresponding secondary antibodies (1:5000, CWBIO) for 60 min at room temperature. Immunoreactive bands were detected using chemiluminescence detection reagents and the density of the immunoreactive bands was measured by a digital visualizer (Eastman Kodak Company, USA). Data were analyzed using ImageJ software version 1.46 (Wayne Rasband, National Institutes of Health, USA). All experiments were repeated three times.

RT-PCR
Total RNA was extracted from renal tissue using TRIzol reagent (TaKaRa, Dalian, China). Total mRNA was reversed transcribed into cDNA using a Transcriptor First Strand cDNA synthesis kit (TaKaRa). Quantitative real-time PCR was performed using SYBR Green PCR master mix (Applied Biosystems) on a BioRadicyclerIQ Detection System. The primer sequences used were as follows: OAT1 forward 5′-GAGCTGTACCCCACAGTGATT-3′, reverse 5′-GAACTCTGCAGTCATACTC-3′; OAT3 forward 5′-GGGTAGAGTCACTGGAACATG-3′, reverse 5′-GGGTAGAGTCACTGGAACATG-3′.

Assessment of Serum Xanthine Oxidase Activity
Serum activity of xanthine oxidase (XOD) was examined using a serum XOD kit according to the instructions provided by the manufacturer.

ELISA Analysis
Multiple renal cytokine levels were measured using appropriate ELISA kits according to the protocols provided by the manufacturer (CUSABIO Technology LLC, Wuhan, China).

Statistical Analysis
All data are presented as mean ± standard error of mean (SEM) and were analyzed using SPSS 20 software. Comparisons between groups were performed using one-way ANOVA. A P-value of p < 0.05 was considered to be statistically significant.

Results
RGTZ Induces PPAR-γ Activation in the Kidneys of Hyperuricemic Rats
To investigate the role of PPAR-γ in the development and progression of HN, we employed a rat model of HN. HN rats were treated daily with 5 mg/kg RGTZ, a PPAR-γ agonist. The expression of PPAR-γ was increased in the kidney of HN rats, and treatment with RGTZ significantly increased PPAR-γ expression (Figure 1). This demonstrated that RGTZ induces PPAR-γ expression in the kidneys of HN rats.

PPAR-γ Activation Improves Renal Function and Alleviates Proteinuria and Renal Damage in HN Rats
Levels of serum creatinine, blood urea nitrogen, and urine microalbumin were significantly increased in the HN group (Figure 2A–C). These results are consistent with previous reports.10 Administration of RGTZ significantly reduced serum creatinine, blood urea nitrogen, and urine microalbumin levels in HN rats (Figure 2A–C). Furthermore, no marked histological changes were observed in the kidneys of sham treated rats who were fed normal chow, and not feed containing a mixture of adenine and potassium oxonate to induce HN (Figure 2D). The main histological disorders observed in the kidney sections from HN rats were severe glomerulosclerosis.
and tubulointerstitial damage with tubular atrophy, tubular dilatation, and interstitial fibrosis (Figure 2D). These lesions and tissue damage were noticeably reduced by treatment with RGTZ. These data demonstrate that PPAR-γ activation through RGTZ treatment exerts a protective effect and attenuates renal damage in this HN model.

**PPAR-γ Activation Attenuates the Progression of Renal Fibrosis in HN Rats**

Renal interstitial fibrosis is characterized by massive accumulation of ECM proteins in interstitial areas and is a common pathological feature of all types of CKD, including HN. We examined ECM protein deposition and expression to explore whether RGTZ alleviated renal fibrogenesis in HN rats. Masson’s trichrome staining showed that renal interstitial fibrosis was significantly more obvious in the HN group compared with the sham and RGTZ treatment groups (Figure 2D and E). Kidneys from rats treated with RGTZ showed significantly improved morphology, with less fibrosis observed in the interstitium (Figure 2D and E). We next explored the effect of RGTZ on collagen I and fibronectin expression by Western blot and immunohistochemistry. Both collagen I and fibronectin expression were increased in the kidneys of HN rats, and administration of RGTZ significantly reduced expression of collagen I and fibronectin (Figure 3). These data demonstrate that PPAR-γ activation attenuates the progression of renal fibrosis and accumulation of ECM proteins in the kidneys of HN rats.

**PPAR-γ Activation Abrogates the TGF-β/Smad3 Signaling Pathway in the Kidneys of HN Rats**

TGF-β/Smad3 signaling pathway plays a critical role in renal fibrosis, but whether RGTZ inhibits uric acid-induced activation of β/Smad3 signaling remains unclear. We first investigated the effects of RGTZ on levels of TGF-β1 in the kidneys of HN rats by Western blot. TGF-β1 expression was upregulated in the kidneys of HN rats, and treatment with RGTZ prevented the upregulation of TGF-β1 protein (Figure 4A and B). Smad3 is the major downstream mediator of TGF-β signaling and directly binds to specific sites in promoter regions to mediate transcription of fibrosis-associated genes, such as collagen I. To further elucidate the effects of RGTZ on renal TGF-β signaling in the HN model, we analyzed the expression of phosphorylated Smad3 (p-Smad3) in kidney
Western blot analysis indicated that the expression of p-Smad3 in the kidneys of HN rat was significantly increased, and that treatment with RGTZ reduced the upregulation of p-Smad3 expression in the HN model (Figure 4C and D). Collectively, these results suggest...

Figure 2 RGTZ improves renal function and alleviates proteinuria and renal damage in HN rats. Levels of (A) serum creatinine, (B) blood urea nitrogen (BUN), and (C) urine microalbumin were examined using biochemical assays. (D) Photomicrographs illustrating hematoxylin–eosin (HE), Masson’s trichrome, and periodic acid–Schiff (PAS) staining of kidney tissue from the different groups (original magnification ×200). (E) Interstitial fibrosis score of kidney tissue from the different groups. RGTZ, rosiglitazone. Data are represented as the mean ± SEM. *p < 0.05 vs sham group; #p < 0.05 vs sham + RGTZ group. **p < 0.05 vs HN group.

tissue from HN rats and HN rats treated with RGTZ.
that PPAR-γ activation can inhibit TGF-β/Smad3 signaling in HN.

PPAR-γ Activation Inhibits Renal Tubular Epithelial-to-Mesenchymal Transition in HN Rats

Renal tubular epithelial-to-mesenchymal transition (EMT) is defined as the process during which renal tubular epithelial cells lose their epithelial phenotype and acquire characteristic mesenchymal features, which leads to the secretion of ECM proteins. Renal tubular EMT plays an important role in the pathogenesis of renal interstitial fibrosis in all types of CKD, including HN. To investigate whether RGTZ inhibits renal tubular EMT in HN rats, we examined expression of E-cadherin, α-SMA, and vimentin in the kidneys of HN rats by Western blot and immunohistochemistry. Western blot of renal tissue showed that RGTZ treatment prevented decreases in E-cadherin, and prevented increases in α-SMA and vimentin expression induced by uric acid (Figure 5A–D). Immunohistochemistry staining revealed that expression of the epithelial marker E-cadherin was evident both in the cell membranes and cytoplasm in normal rat kidneys (Figure 5E), while kidneys of HN rats had reduced E-cadherin expression at 3 weeks (Figure 5E). Meanwhile, some tubules in kidneys of HN rats exhibited de novo staining of α-SMA, a marker of mesenchymal cells (Figure 5E). Treatment with RGTZ significantly increased E-cadherin expression and decreased α-SMA expression in kidney tissue of HN rats. These findings suggest that renal tubular EMT occurs in the kidneys of HN rats, and that PPAR-γ activation inhibits renal tubular EMT in the kidneys of HN animals.

PPAR-γ Activation Inhibits NF-κB Pathway Activation and Macrophage Infiltration in the Kidneys of HN Rats

NF-κB is a transcription factor and regulator of many genes, and is involved in the inflammatory response. NF-κB activation increases leukocyte infiltration and cytokine and chemokine expression. Expression of p-NF-κB (p65) was increased in the kidneys of HN rats, and this increase was significantly downregulated by RGTZ (Figure 6A and B). Inflammatory cell infiltration in the renal interstitium is a common pathologic feature of CKD, including HN. To assess whether RGTZ inhibited macrophage infiltration in HN, CD68, which is a marker of active macrophages, was examined by
immunohistochemistry. The number of infiltrated macrophages was increased in the kidneys of HN rats, and was significantly decreased by treatment with RGTZ (Figure 6C). These results show that PPAR-γ activation can inhibit the NF-κB signaling pathway and macrophage infiltration in the kidneys of HN rats.

PPAR-γ Activation Inhibits the Release of Cytokines/Chemokines in the Kidney of HN Rats

The production of proinflammatory cytokines/chemokines is a key initiating step in renal fibrogenesis. Therefore, we examined the expression of some proinflammatory cytokines/chemokines, including MCP-1, RANTES, TNF-α, and IL-1β, in the kidney by enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of these molecules were significantly increased in the kidney of HN rats. Administration of RGTZ to HN rats resulted in decreased MCP-1, ICAM-1, TNF-α, and IL-1β levels (Figure 7). These data demonstrate that PPAR-γ activation suppresses the expression of proinflammatory cytokines/chemokines in the HN rat model.

PPAR-γ Activation Decreases Serum Uric Acid and Preserves Expression of Urate Transporters Expression in the Kidneys of HN Rats

After three weeks of daily feeding with a mixture of adenine and potassium oxonate, serum uric acid levels were significantly increased, and urinary uric acid levels were significantly decreased (Figure 8A and B). RGTZ treatment dramatically reduced serum uric acid levels and increased urinary uric acid, which is consistent with the inhibitory effects of RGTZ on renal dysfunction. Urate transporters, including OAT1 and OAT3, promote uric acid excretion and play a critical role in uric acid homeostasis. Therefore, we assessed the effects of RGTZ on expression of OAT1 and OAT3 in the kidneys of HN rats. The expression of OAT1 and OAT3 were significantly reduced in the kidneys of HN, and administration of RGTZ partially rescued expression of OAT1 and OAT3 (Figure 8C and D). Increased uric acid production is also associated with hyperuricemia, and is commonly associated with upregulation of serum XOD activity.
Therefore, we assessed the effects of RGTZ on serum XOD activity in HN rats. The activity of serum XOD was increased in the kidneys of HN rats, and RGTZ administration was ineffective in reducing the increase in activity of serum XOD in the HN model (Figure 8E). These data demonstrated that PPAR-\(\gamma\) activation decreases serum uric acid and promotes uric acid excretion through preservation of OAT1 and OAT3 expression.

**Discussion**

In the present study, we investigated the effects of PPAR-\(\gamma\) activation on the development and pathological mechanisms of HN. We demonstrated that treatment with RGTZ, a highly selective PPAR-\(\gamma\) agonist, improves renal function, decreases urine microalbumin levels, and inhibits interstitial fibrosis and macrophage infiltration in kidney tissue in a rat model of HN. Additionally, we report that
RGTZ treatment reduces TGF-β expression and NF-κB pathway activation, decreases expression of fibronectin, collagen I, α-SMA, vimentin, MCP-1, RANTES, TNF-α, and IL-1β, and increases E-cadherin expression in the kidneys of HN rats. Furthermore, we showed that RGTZ treatment decreases serum uric acid and promotes renal excretion of uric acid through preservation of OAT1 and OAT3 expression.

Interstitial fibrosis is a reliable prognostic indicator and a major determinant of renal insufficiency, and is the ultimate pathological outcome of most kinds of CKD, including HN. TGF-β has a central role in glomerulosclerosis and interstitial fibrosis, and influences increased matrix protein synthesis, suppression of matrix degradation, and changing cell-cell interactions in various kidney diseases.

Abnormal and excessive accumulation of ECM in glomeruli and in renal tubulo-interstitial regions exacerbates the seriousness of kidney injury, and are typical characteristics of renal fibrosis. In a study by Choi et al, PPAR-γ activation inhibits dimethylnitrosamine-induced hepatic fibrosis by inhibiting the TGF-β1/Smad pathway. Jiang et al found that PPAR-γ agonist treatment significantly attenuated renal interstitial fibrosis by reducing the expression of TGF-β, collagen IV, and fibronectin in kidneys in a rat model of unilateral ureteral obstruction. In our study, we observed enhanced TGF-β activation, diffuse interstitial fibrosis, and increased expression of collagen I and fibronectin in kidneys in a rat model of HN. Moreover, administration of RGTZ dramatically suppressed TGF-β activation, alleviated interstitial fibrosis, and decreased expression of collagen I and fibronectin in renal tissue of HN rats.

Renal tubular EMT is a prominent source of fibroblasts and an important event in the pathogenesis of renal interstitial fibrosis in CKD. A report by Lee et al suggested that high glucose-induced EMT was ameliorated by the PPAR-γ agonist troglitazone in a primary culture model of renal tubular epithelial cells. PPAR-γ activation reduced renal fibrosis induced by perfluorooctanesulfonate by regulating EMT. In our study, we report that a significant reduction of E-cadherin expression and an increase of α-SMA and vimentin expression in the kidneys of HN rats. These findings suggested that renal tubular EMT may participate in the progression of HN in rats. Our study demonstrated that RGTZ can attenuate renal tubular EMT in HN rats, evidenced by increased E-cadherin expression and decreased α-SMA and vimentin expression in kidney tissue. The suppression of renal EMT may represent the mechanism by which RGTZ attenuates renal fibrosis in HN.

Hyperuricemia has been shown to induce inflammatory responses, leading to kidney injury. Activation of the NF-κB pathway plays a crucial role in the hyperuricemia-induced inflammatory response, and increases expression of pro-inflammatory cytokines and chemokines. In
a study by Zhu et al, PPAR-γ activation induced an anti-inflammatory effect by inhibiting the NF-κB pathway in chronic asthma models.\(^\text{40}\) It has been also reported that RGTZ suppresses LPS-mediated inflammatory responses, indicating that PPAR-γ agonists may be effective protection against pulmonary inflammation in rats.\(^\text{41}\) Moreover, our previous study in a chronic renal allograft dysfunction model demonstrated that PPAR-γ agonists inhibit NF-κB activation and infiltration of inflammatory cells into the interstitium.\(^\text{42}\) In the present study, we showed that activation of PPAR-γ with RGTZ inhibits NF-κB activation, macrophage infiltration, and reduces expression of MCP-1, RANTES, TNF-α, and IL-1β induced by hyperuricemia. These data suggest that inhibition of the inflammatory response may be another mechanism by which RGTZ attenuates the renal fibrosis and the development of HN.

Hyperuricemia is an independent risk factor for renal damage and can exacerbate the progression of kidney fibrosis and progressive CKD.\(^\text{1}\) Therapies that lower uric acid may retard the progression of CKD.\(^\text{43,44}\) In the present study, we found that RGTZ dramatically reduced serum uric acid levels in HN rats, which was consistent with the inhibitory effect of RGTZ on renal dysfunction. Previous studies in patients with type 2 diabetes mellitus demonstrated that RGTZ treatment decreases levels of serum urate.\(^\text{45}\) However, the mechanism by which RGTZ decreases serum uric acid levels remains unclear. Serum uric acid levels are largely determined by uric acid production and renal excretion. OAT1 and OAT3 are two primary organic anion transporters, that play a critical role in the excretion of uric acid, and aberrant expression of OAT1 and OAT3 causes excessive uric acid accumulation leading to hyperuricemia.\(^\text{3}\) In the present study, we demonstrate that expression of OAT1 and OAT3 is decreased in the kidney tissue of HN rats, and we show that OAT1 and OAT3 expression is partially restored by RGTZ treatment. We also examined the effects of RGTZ on the activity of serum XOD,
a fundamental enzyme that promotes the production of serum uric acid. Our data indicated that the activity of serum XOD is significantly increased in HN rats. However, RGTZ administration was ineffective in reducing the activity of serum XOD in HN rats. These results suggest that RGTZ decreases serum uric acid and promotes uric acid excretion through preservation of OAT1 and OAT3 expression, which may constitute a mechanism by which RGTZ attenuates hyperuricemia-associated renal injury.

In conclusion, our results demonstrate that RGTZ attenuates the progression of HN in a rat model through multiple mechanisms, including inhibition of TGF-β signaling, inhibiting renal tubular EMT and inflammation, and lowering serum uric acid levels by preserving expression of urate transporters.

**Acknowledgments**

This work was supported by Risk factors and prediction model of chronic kidney disease caused by metabolic syndrome: A multicentric prospective cohort study clinical trial training project of Southern Medical University (LC2016PY047, 2016), the Science and Technique Program of Guangzhou (201604020015, 2015), the South Wisdom Valley Innovative Research Team Program (CXTD-004, 2014), and The National Natural Science Foundation of China (81873620).

**Disclosure**

Xin Wang and Jin Deng are co-first authors. The authors report no conflicts of interest in this work.

**References**

1. Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. *Am J Kidney Dis*. 2018;71(3):362–370. doi:10.1053/j.ajkd.2017.08.017
2. Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. *Am J Kidney Dis*. 2018;71(6):851–865. doi:10.1053/j.ajkd.2017.12.009
3. Otani N, Ouchi M, Hayashi K, Jutabha P, Anzai N. Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. *Anat Sci Int*. 2017;92(2):200–206.
4. Huijuan W, Xiaoxu C, Rui S, Xinghui L, Beibei T, Jianchun M. Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats. *Biomed Pharmacother*. 2017;91:358–365. doi:10.1016/j.biopha.2017.04.031
Wang et al

5. Lovisa S, LeBlu VS, Tampe B, Sugimoto H, Vadnaga K, Carstens JL. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. *Nat Med*. 2015;21(9):998–1009. doi:10.1038/nm.3902

6. Stone RC, Pastar I, Ojeh N, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. *Cell Tissue Res*. 2016;365(3):495–506. doi:10.1007/s00441-016-2464-0

7. Meng XM, Tang PM, Li J, Lan HY. TGF-beta/Smad signaling in renal fibrosis. *Front Physiol*. 2015;6:82. doi:10.3389/fphys.2015.00082

8. Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. *Am J Physiol Renal Physiol*. 2013;304(5):F471–480. doi:10.1152/ajprenal.00560.2012

9. Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. *Nephrol Dial Transplant*. 2014;29(3):507–514. doi:10.1093/ndt/gft248

10. Liu N, Wang L, Yang T, et al. EGF receptor inhibition alleviates LPS-mediated inflammation via activating the TLR4/NF-kB signaling pathway. *Dovepress*. 2014;506. doi:10.7150/tip.10799

11. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. PPAR gamma as a therapeutic agent for angiotensin II-induced cardiac fibrosis. *Am J Physiol Heart Circ Physiol*. 2010;298(5):F1263–F1274. doi:10.1152/ajpheart.00475.2009

12. Liang X, Liao Y, Wang H, et al. Autophagy regulates TGF-beta-Smad3 signaling and suppresses kidney fibrosis induced by unilateral ureteral obstruction. *J Am Soc Nephrol*. 2014;25(12):2835–2846. doi:10.1681/ASN.2013101068

13. Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis. *Kidney Int Suppl*. 2015;480. doi:10.1016/j.kipps.2014.04.001

14. Gutting T, Weber CA, Weidner P, et al. PPARgamma-activation increases intestinal M1 macrophages and mitigates formation of serratd ademomas in mutant KRAS mice. *Oncoimmunology*. 2018;7(5):e1423168. doi:10.1080/21626402.X.2017.1423168

15. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. *Drug Design, Development and Therapy*. 2020;14:326. doi:10.2147/dddt.s16995

16. Lee YJ, Marini MA, Mancuso E, et al. Uric acid is associated with renal fibrosis and progression of hyperuricemic nephropathy. *Sci Rep*. 2017;7(1):1223. doi:10.1038/s41598-017-01289-0

17. Eddy AA. Overview of the cellular and molecular basis of kidney injury. *J Histochem Cytochem*. 2015;63(6):551–562. doi:10.1389/jhc.2015.00050

18. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of in renal fibrosis. *Nat Rev Nephrol*. 2014;10(9):493–503. doi:10.1038/nrneph.2014.114

19. Ding Y, Kim S, Lee SY, Koo JK, Wang Z, Choi ME. Autophagy regulates TGF-beta/Smad3 signaling in renal fibrosis via activating the TLR4/NF-kB signaling pathway. *Am J Physiol Renal Physiol*. 2013;305(6):F1263–F1274. doi:10.1152/ajprenal.00560.2012

20. Mitchell JP, Carmody RJ. NF-kB and the transcriptional control of in inflammatory processes in renal fibrosis. *Nat Rev Nephrol*. 2014;10(9):493–503. doi:10.1038/nrneph.2014.114

21. Liu N, Xu L, Shi Y, et al. Pharmacologic targeting of ERK1/2 attenuates the development and progression of hyperemic nephrinopathy in rats. *Oncotarget*. 2017;8(20):33807–33826. doi:10.18632/oncotarget.16995

22. Black LM, Lever JM, Agarwal A. Renal inflammation and fibrosis: a double-edged sword. *J Histchem Cytochem*. 2017;65(9):663–681. doi:10.1369/0022155148982932

23. Wu W, Bush KT, Nigam SK. Key role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes. *Sci Rep*. 2017;7(1):4939. doi:10.1038/s41598-017-04949-2

24. Liu Y. Cellular and molecular mechanisms of renal fibrosis. *Nat Rev Nephrol*. 2011;7(12):684–696. doi:10.1038/nrneph.2011.149

25. Isaka Y. Targeting TGF-beta signaling in kidney fibrosis. *Int J Mol Sci*. 2018;19(9):2532. doi:10.3390/ijms19092532

26. Toba H, Lindsey ML. Extracellular matrix roles in cardiofibrosis: potential therapeutic targets for CVD and CKD in the elderly. *Pharmacol Ther*. 2019;193:99–120. doi:10.1016/j.pharmthera.2018.08.014

27. Sun YBY, Xu Q, Caruana G, Li J. The origin of renal fibroblasts/ myofibroblasts and the signals that trigger fibrosis. *Differentiation*. 2016;92(3):102–107. doi:10.1016/j.diff.2016.05.008

28. Choi JH, Jin SW, Choe CY, et al. Capsaicin inhibits dimethyluricamide-induced hepatic fibrosis by inhibiting the TGF-beta/Smad pathway via peroxisome proliferator-activated receptor gamma activation. *J Agric Food Chem*. 2017;65(2):317–326. doi:10.1021/acs.jafc.6b04805

29. Jiang L, Chen XP, Long YB, et al. The potential signaling pathway between peroxisome proliferator-activated receptor gamma and retinoic acid receptor alpha in renal interstitial fibrosis disease. *J Recept Signal Transduct Res*. 2015;35(4):258–268. doi:10.3109/10799893.2014.975249

30. Lee YJ, Han HJ. Targlitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through P3K-Akt, GSK-3β, Snail-1, and β-catenin in renal proximal tubule cells. *Am J Physiol Renal Physiol*. 2010;298(5):F1263–1275. doi:10.1152/ajprenal.00475.2009

31. Chou HC, Wen LL, Chang CC, Lin CY, Jin L, Juan SH. From the cover: l-carnitine via ppar-o and sirt1-dependent mechanisms attenuates epithelial-mesenchymal transition and renal fibrosis caused by perflurooctane sulfonate. *Toxicol Sci*. 2017;160(2):217–229. doi:10.1093/toxsci/kfx183

32. Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. *Am J Kidney Dis*. 2013;61(1):134–146. doi:10.1053/j.ajkd.2012.07.021

33. Spiga R, Marini MA, Mancuso E, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-kappab signaling pathway in HepG2 cells. *Arterioscler Thromb Vasc Biol*. 2017;37(6):1241–1249. doi:10.1161/ATVBAHA.117.309128

34. Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-kappab signaling pathway. *PLoS One*. 2012;7(6):e39738. doi:10.1371/journal.pone.0039738

35. Liu H, Xiong J, He T, et al. high uric acid-induced epithelial-mesenchymal transition of renal tubular epithelial cells via the TLR4/NF-kB signaling pathway. *Am J Physiol Renal Physiol*. 2017;49(4):333–342. doi:10.1159/000481668

36. Zhu T, Chen Z, Chen G, et al. Curcumin attenuates asthmatic airway inflammation and mucus hypersecretion involving a PPAR-dependent NF-B signaling pathway in vivo and in vitro. *Mediators Inflamm*. 2019;2019:4927430. doi:10.1155/2019/4927430

37. Cho RL, Yang CC, Tseng HC, Hsiao LD, Lin CC, Yang CM. Haem oxygenase-1 up-regulation by rosiglitazone via ROS-dependent Nrf2-antioxidant response elements axis or PPARγ attenuates LPS-mediated lung inflammation. *Br J Pharmacol*. 2018;175(20):3928–3946. doi:10.1111/bph.14465

For personal use only.
42. Deng J, Xia Y, Zhou Q, et al. Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats. *Transpl Immunol*. 2019;54:20–28. doi:10.1016/j.trim.2019.01.002

43. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. *Nephrol Dial Transplant*. 2014;29(2):406–413. doi:10.1093/ndt/gft378

44. Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. *Cochrane Database Syst Rev*. 2017;10:Cd009460.

45. Bao Y, Zhao T, Wang X, et al. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. *J Proteome Res*. 2009;8(4):1623–1630. doi:10.1021/pr800643w